Our innovation: A wide range of capabilities are available at Novo Nordisk Pharmatech A/S within the various departments; Sales and Marketing, R&D, Manufacturing, Quality, Business Support and HR & Communication. They are all critical for us to run the business and innovate. The following “Core Capabilities” are fundamental to the future growth of our company:
Designing and developing silica gels: We have long history of continuously reducing the cost for Novo Nordisk of producing insulin by providing robust silica gel and developing processes for increasing their life time.
Advanced microanalysis: At our Microanalysis Centre our team supports Novo Nordisk with state-of-the-art microscopy and spectroscopic support. This capability is also critical for the development of new chromatographic resins.
Organic chemical synthesis manufacturing: We have from the outset produced Quats by organic synthesis manufacturing and has led to our solid experience.
cGMP embedded throughout the organisation: Biopharmaceutical companies are required to operate in accordance to cGMP to ensure patient safety. For us to be a preferred supplier to the biopharmaceutical industry cGMP therefore is a key capability.
Contact us for further information here.